Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence (COVID-19)

NCT04721444 | Completed

• 1 other identifier: 5293
• Study Type: observational
• Target: 1,211
• Locations: 1 country
• Sites: 3

Brief Summary

Distinguishing changes on patients that have received thoracic radiotherapy and patients that are currently receiving or have recently received IO and presenting lung changes which will be identified using AI.

Conditions

Lung Cancer; Covid19; Pneumonitis

Outcome Measures

Primary Outcomes (2)

• Development of a Machine Learning model to distinguish parenchymal lung changes

  The development and validation of an ML/radiomic classifier to distinguish between Infective/COVID-19 pneumonia and cancer therapy induced lung changes

  3 years

• Development of a Machine Learning model to predict recurrence risk after radical radiotherapy for non-small cell lung cancer

  to develop a prognostic AI/radiomic signature for NSCLC recurrence after radical RT (Conventional fractionated RT +/- chemotherapy or stereotactic body RT (SBRT)) to stratify appropriate surveillance and onward care, thus minimising unnecessary hospital visits and resource use.

  3 years

Study Arms (7)

Arm A - Cohort A1

Training set: Pneumonitis in the context of IO therapy and negative for infectious pneumonia (including COVID-19)

Diagnostic Test: Machine Learning Classification of parenchymal lung change cause

Arms A and B - Cohort B1

Training set B1: IO and RT naive and pneumonia (without COVID-19)

Diagnostic Test: Machine Learning Classification of parenchymal lung change cause

Arms A and B - Cohort B2

Training set B2: IO and RT naive and confirmed COVID-19 positive with pneumonia

Diagnostic Test: Machine Learning Classification of parenchymal lung change cause

Arm B - Cohort A2

Training set: Pneumonitis in the context of thoracic RT and negative for infectious pneumonia (including COVID-19)

Diagnostic Test: Machine Learning Classification of parenchymal lung change cause

Arm A - Test Cohort (Cohort C1)

Test set C1: Patients on IO and with possible toxicity versus COVID-19 or other infective pneumonitis

Diagnostic Test: Machine Learning Classification of parenchymal lung change cause

Arm B - Test Cohort (Cohort C2)

Test set C2: Patients with pneumonitis in context of thoracic RT with possible toxicity versus COVID-19 or other infective pneumonitis.

Diagnostic Test: Machine Learning Classification of parenchymal lung change cause

Arm C

Patients with radiotherapy planning CT scans and post-treatment surveillance CT scans at 3, 6 and 12-months post treatment

Diagnostic Test: Machine Learning Classification of recurrence and non-recurrence

Interventions

Machine Learning Classification of parenchymal lung change cause DIAGNOSTIC_TEST

Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.

Arm A - Cohort A1; Arm A - Test Cohort (Cohort C1); Arm B - Cohort A2; Arm B - Test Cohort (Cohort C2); Arms A and B - Cohort B1; Arms A and B - Cohort B2

Machine Learning Classification of recurrence and non-recurrence DIAGNOSTIC_TEST

Arm C: Radiomics and deep-learning approaches will be used on patient's imaging to develop a risk-signature for recurrence of malignancy following radical treatment

Arm C

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Arms A and B: Adult patients with pneumonitis that have previously been treated with thoracic radiotherapy or immunotherapy Arm C: Adult patients that have received radical radiotherapy for NSCLC

You may qualify if:

• Cohort A1 (from Arm A) - Immunotherapy (IO) pneumonitis cases: patients currently on or having received ICI IO in the last 3 months of presentation with:
• New radiological lung changes on CT/CXR (confirmed on report) of a severity and distribution consistent with IO pneumonitis. These changes should be of severity and distribution that are not incompatible with viral or lower respiratory tract infection.
• AND Must not have had RT involving the thorax (unless this was breast/chest wall RT more than 5 years ago, which is permissible) AND
• Where there is documented clinical concern for infection, have undergone one or more laboratory investigations for viral or lower respiratory tract infection including, but not limited to Nasopharyngeal aspirate or swab for respiratory virus by PCR; Sputum sample or bronchial washings MCS with no organism(s) consistent with lower respiratory tract infection, cytology or beta-glucan/galactomannan for PCP or fungal infection; broncho-alveolar lavage for markers of infection such as MCS, PCR, fungal culture, beta-glucan/galactomannan for PCP or evidence of lower respiratory tract infection (including invasive fungal infection) by cytology, none of which were considered positive for infection by the clinical team.
• Where empirical antibiotics were prescribed, patients must either have had a negative BAL infection screen or may be included at the discretion of the local site PI and local radiologist with lung interest or two members of the trial management group, one of whom must be a radiologist with lung interest or respiratory physician or oncologist with suitable experience of thoracic CT imaging, after after review of the case-notes.
• Prophylactic co-trimoxazole prescribed in the context of high-dose steroid therapy is permitted.
• Cohort A2 (from Arm B) - Radiotherapy (RT) pneumonits cases: Patients that have completed a course of RT involving the thorax (e.g. lung, breast, oesophageal RT) in the last 12 months prior to presentation, that have not received immunotherapy, with:.
• New radiological lung changes on CT/CXR (confirmed on report) of a severity and distribution consistent with radiation pneumonitis or early fibrosis (should not include established fibrosis). These changes should be of severity and distribution that are not incompatible with viral or lower respiratory tract infection.
• AND
• Where there is documented clinical concern for infection, have undergone one or more laboratory investigations for viral or lower respiratory tract infection including, but not limited to Nasopharyngeal aspirate or swab for respiratory virus by PCR; Sputum sample or bronchial washings MCS with no organism(s) consistent with lower respiratory tract infection, cytology or beta-glucan/galactomannan for PCP or fungal infection; broncho-alveolar lavage (BAL) for markers of infection such as MCS, PCR, fungal culture, beta-glucan/galactomannan for Pneumocystis Pneumonia (PCP) or evidence of lower respiratory tract infection (including invasive fungal infection) by cytology, none of which were considered positive for infection by the clinical team. Where empirical antibiotics were prescribed, patients must either have had a negative BAL infection screen or may be included at the discretion of the local site PI and local radiologist with lung interest or two members of the trial management group, one of whom must be a radiologist with lung interest or respiratory physician or oncologist with suitable experience of thoracic CT imaging, after review of the case-notes.
• Prophylactic co-trimoxazole prescribed in the context of high-dose steroid therapy is permitted.
• B1 (Utilised in Arms A \& B) Non-COVID-19 infective cases:
• New radiological lung changes on CT/CXR (confirmed on report) of a severity and distribution consistent with lower respiratory tract infection but compatible with the grade and nature of pneumonitis seen with IO or RT
• AND
• Laboratory findings that fulfil one or more of the following criteria of infection: Nasopharyngeal aspirate or swab positive for a respiratory virus by PCR; Sputum sample or bronchial washings positive MCS for an organism(s) consistent with lower respiratory tract infection, cytology or beta-glucan/galactomannan positive for PCP or fungal infection, positive urine legionella/pneumococcal antigen screen, positive serology for mycoplasma pneumonia; broncho-alveolar lavage for markers of infection (MCS, PCR, fungal culture, beta-glucan/galactomannan for PCP or other evidence of lower respiratory tract infection (including invasive fungal infection) by cytology. Where no such laboratory findings were positive but the patient improved with anti-microbial therapy, such cases may be included at the discretion of the local site PI and local radiologist with lung interest or two members of the trial management group two members of the trial management group, one of whom must be a radiologist with a lung interest or respiratory physician or oncologist with suitable experience of thoracic CT imaging, after review of the case-notes and imaging.

You may not qualify if:

• Patients with documented past medical history of congestive cardiac failure or other cause for interstitial lung disease
• Arm C:
• Adult patients (aged 18 or over) treated with radical thoracic RT (conventional fractionated RT +/- chemotherapy or SBRT) for NSCLC
• RT planning scan imaging and labelled structure set data available from participating centre
• Minimum 2 years of post-RT follow-up data including clinical or histological confirmation in the case of recurrence and whether the patient is alive as available from primary care or hospital records.
• Patients with post-treatment surveillance CT imaging (minimum of first scan post-treatment and where available +/- further scans within 2 years post-RT, e.g. at 3/6/12 months post-treatment).
• Any patient that does not have a primary lung mass e.g. Tx disease
• Any patient being treated for recurrence of a previously treated lung cancer
• Any patient that did not have radical RT e.g. patients that had high dose palliative RT
• Any patient that does not have imaging that meets technical requirements within the imaging processing and analysis manual

Sponsors & Collaborators

• Royal Marsden NHS Foundation Trust: lead

Study Sites (3)

Guys and St. Thomas' NHS Foundation Trust

London, United Kingdom

Location

Imperial College Healthcare NHS Trust

London, United Kingdom

Location

Royal Marsden NHS Foundation Trust

London, United Kingdom

Location

MeSH Terms

Conditions

Lung Neoplasms; COVID-19; Pneumonia

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Pneumonia, Viral; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections

Study Officials

• Richard Lee

  Royal Marsden NHS Foundation Trust

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 6, 2020
• First Posted: January 22, 2021
• Study Start: January 27, 2021
• Primary Completion: March 1, 2022
• Study Completion: March 1, 2022
• Last Updated: June 29, 2022

Record last verified: 2022-06

Locations

GB (3)